Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism

• Status: Completed
• Trial end date: 2007-05-01
• Target enrollment: 0
• Participant gender: Male

Summary

Subjects who completed ZA-003 were eligible to receive an additional year of treatment in this extension study.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Repros Therapeutics Inc.
• Treatments: Citric Acid; Clomiphene; Enclomiphene; Sodium Citrate; Zuclomiphene

Criteria

Inclusion Criteria:

• Total serum testosterone concentrations < 300 ng/dL at baseline

Exclusion Criteria:

• Presence or history of prostate cancer

• Elevated PSA > 3.5 ng/mL

Additional inclusion and exclusion criteria may apply.